Results 1 to 10 of about 34,512 (245)

Mutant IDH1 is required for IDH1 mutated tumor cell growth [PDF]

Oncotarget, 2012
Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protein is required for maintaining IDH1 mutated tumor cell growth remains unknown.
Genglin Jin, Christopher J. Pirozzi, Lee H. Chen, Giselle Y. López, Christopher G. Duncan, Jie Feng, Ivan Spasojević, Darell D. Bigner, Yiping He, Hai Yan   +9 more
openalex   +5 more sources

IDH1 and IDH2 Mutations in Gliomas [PDF]

Current Neurology and Neuroscience Reports, 2013
Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2008, occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. These mutations, which occur early in gliomagenesis, change the function of the enzymes, causing them to produce 2-hydroxyglutarate, a possible oncometabolite, and to not produce NADPH ...
Adam L. Cohen, Sheri L. Holmen, Howard Colman   +2 more
openalex   +5 more sources

Expanding the spectrum of IDH1 mutations in gliomas [PDF]

Modern Pathology, 2013
Mutations in isocitrate dehydrogenase -1 or -2 (IDH1 or IDH2) are found in the majority of WHO grade II and III diffuse gliomas and secondary glioblastomas. IDH mutation screening is rapidly becoming part of the routine pathological work up of human brain tumors, providing both diagnostic and prognostic information.
Ruta Gupta, Simon Flanagan, Cheryl C. Y. Li, Maggie Lee, Brindha Shivalingham, Sanaz Maleki, Helen Wheeler, Michael E. Buckland   +7 more
openalex   +4 more sources

Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle [PDF]

Nature Communications
Metabolic dysfunction–associated steatotic liver disease (MASLD), potentially ameliorated by bariatric-metabolic surgery, remains a global health concern in the absence of approved drugs.
Shanshan Liu, Yu Ji, Luyang Wei, Yiqiao Zhang, Linghang Zeng, Yiyang Min, Danyang Yin, Kun Liu, Chengjian Guan, Shumeng Liu, Huajing Yu, Zhongtao Zhang   +11 more
doaj   +2 more sources

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma

Translational Oncology, 2020
Isocitrate dehydrogenase (IDH) mutations occur frequently in lower-grade gliomas, which result in genome-wide epigenetic alterations. The wild-type IDH1 is reported to participate in lipid biosynthesis and amino acid metabolism, but its role in ...
Chao Sun, Liming Xiao, Yuanlin Zhao, Jiankuan Shi, Yuan Yuan, Yu Gu, Feng Zhang, Xing Gao, Ying Yang, Risheng Yang, Junhui Qin, Jin Zhang, Chao Wang, Yingmei Wang, Zhe Wang, Peizhen Hu, Ting Chang, Liang Wang, Gang Wang, Huangtao Chen, Zhuyi Li, Jing Ye   +21 more
doaj   +3 more sources

The expression and significance of IDH1 and p53 in osteosarcoma [PDF]

Journal of Experimental & Clinical Cancer Research, 2010
Background To detect the expression of isocitrate dehydrogenase 1 (IDH1) and transformation-related protein 53 (p53) in osteosarcoma and analyze the correlation between them and the clinico-pathological features.
Zhou Min, Wu Gang, Fu Tao, Qi Bai-Wen, Yu Ai-Xi, Hu Xiang, Luo Jun, Xu Jun-Hua   +7 more
doaj   +4 more sources

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Cancer Research, 2015
Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1R132H that are being developed for cancer therapy may ...
Remco J. Molenaar, Dennis Botman, Myrthe A J Smits, Vashendriya V.V. Hira, Sanne A. M. van Lith, Jan Stap, Peter Henneman, Mohammed Khurshed, Krissie Lenting, Adri N. Mul, Dionysia Dimitrakopoulou, Cornelis M. van Drunen, Ron A. Hoebe, Tomas Radivoyevitch, Johanna W. Wilmink, Jaroslaw P. Maciejewski, W. Peter Vandertop, William P. J. Leenders, Fonnet E. Bleeker, Cornelis J.F. Van Noorden   +19 more
openalex   +6 more sources

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations [PDF]

Acta Neuropathologica, 2021
AbstractSomatic mutations in the isocitrate dehydrogenase genesIDH1andIDH2occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that gliomas are the only tumour type with an exceptionally high percentage of IDH1R132Hmutations.
Jan Oosting, Filip de Vos, Michael A. Vogelbaum, C Mircea S Tesileanu, Jaap C. Reijneveld, Martin J B Taphoorn, Thierry Gorlia, Robert B. Jenkins, Sara Erridge, Wolfgang Wick, Hendrikus J. Dubbink, Elizabeth Lim, Johan M. Kros, Paul Clement, Lorenzo Boggiani, Matthew E. Griffin, Jean Francais Baurain, Anna K. Nowak, Anna K. Nowak, Anna K. Nowak, Wies Vallentgoed, Martin J. van den Bent, Francesca Caparrotti, Anja Gijtenbeek, Pim J. French, Thierry Lesimple, Olivier Chinot, Michael Weller, Iris de Heer, Judith V.M.G. Bovée, Vassilis Golfinopoulos, Alba A. Brandes, Roelien H. Enting, Roberta Rudà, Sanjeev Gill, Paul Mulholland, Leland Rogers, Sanne Venneker, Kenneth Aldape, Marc Sanson, Pieter Wesseling, Susan Clenton, Warren P. Mason, Maurice de Wit, Youri Hoogstrate, Catherine McBain, Helen Wheeler, Walter Taal, Brigitta G. Baumert   +48 more
openaire   +15 more sources

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia [PDF]

Annals of Hematology, 2020
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has ...
Gupta, Charu, Kaulfuss, Stefan, Görlich, Kerstin, Othman, Basem, Chaturvedi, Anuhar, Heuser, Michael   +5 more
openaire   +4 more sources

Characterization of the human IDH1 gene promoter

AIMS Molecular Science, 2023
In cancer, the production of ATP depends mainly on glycolysis, usually accompanied by the dysfunction of the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS).
Yutaka Takihara, Ryuji Otani , Takuro Ishii, Shunsuke Takaoka, Yuki Nakano , Kaori Inoue, Steven Larsen, Yoko Ogino , Masashi Asai , Sei-ichi Tanuma , Fumiaki Uchiumi   +10 more
doaj   +1 more source